Heidelberg Pharma AG (HPHA.DE)
EUR 2.97
(-1.0%)
EUR 2.97
(-1.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.01 Million EUR | -38.08% |
| 2022 | 33.93 Million EUR | 125.75% |
| 2021 | 15.03 Million EUR | 123.39% |
| 2020 | 6.72 Million EUR | 0.49% |
| 2019 | 6.69 Million EUR | 26.22% |
| 2018 | 5.3 Million EUR | 18.81% |
| 2017 | 4.46 Million EUR | -18.58% |
| 2016 | 5.48 Million EUR | 109.22% |
| 2015 | 2.62 Million EUR | -16.87% |
| 2014 | 3.15 Million EUR | -57.16% |
| 2013 | 7.36 Million EUR | -58.64% |
| 2012 | 17.8 Million EUR | -29.75% |
| 2011 | 25.33 Million EUR | 267.95% |
| 2010 | 6.88 Million EUR | -23.21% |
| 2009 | 8.96 Million EUR | -5.98% |
| 2008 | 9.53 Million EUR | -18.32% |
| 2007 | 11.67 Million EUR | -2.59% |
| 2006 | 11.98 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 16.55 Million EUR | -21.23% |
| 2024 Q2 | 30.81 Million EUR | 86.14% |
| 2024 Q3 | 29.95 Million EUR | -2.79% |
| 2023 Q3 | 22.84 Million EUR | -15.64% |
| 2023 Q2 | 27.07 Million EUR | 2.9% |
| 2023 Q1 | 26.31 Million EUR | -22.47% |
| 2023 FY | 21.01 Million EUR | -38.08% |
| 2023 Q4 | 21.01 Million EUR | -8.0% |
| 2022 Q4 | 33.93 Million EUR | -5.41% |
| 2022 Q3 | 35.87 Million EUR | 1.03% |
| 2022 FY | 33.93 Million EUR | 125.75% |
| 2022 Q1 | 21.01 Million EUR | 39.8% |
| 2022 Q2 | 35.51 Million EUR | 68.98% |
| 2021 Q1 | 10.91 Million EUR | 62.16% |
| 2021 Q4 | 15.03 Million EUR | 1.58% |
| 2021 Q2 | 15.76 Million EUR | 44.47% |
| 2021 FY | 15.03 Million EUR | 123.39% |
| 2021 Q3 | 14.79 Million EUR | -6.13% |
| 2020 Q4 | 6.72 Million EUR | -0.95% |
| 2020 Q1 | 7.12 Million EUR | 6.42% |
| 2020 FY | 6.72 Million EUR | 0.49% |
| 2020 Q2 | 7.54 Million EUR | 5.86% |
| 2020 Q3 | 6.79 Million EUR | -9.95% |
| 2019 Q2 | 5.39 Million EUR | -0.36% |
| 2019 FY | 6.69 Million EUR | 26.22% |
| 2019 Q1 | 5.4 Million EUR | 1.95% |
| 2019 Q3 | 5.33 Million EUR | -1.11% |
| 2019 Q4 | 6.69 Million EUR | 25.64% |
| 2018 FY | 5.3 Million EUR | 18.81% |
| 2018 Q4 | 5.3 Million EUR | 8.9% |
| 2018 Q2 | 4.34 Million EUR | 26.97% |
| 2018 Q3 | 4.87 Million EUR | 12.12% |
| 2018 Q1 | 3.42 Million EUR | -23.37% |
| 2017 FY | 4.46 Million EUR | -18.58% |
| 2017 Q4 | 4.46 Million EUR | -43.5% |
| 2017 Q3 | 7.9 Million EUR | 39.91% |
| 2017 Q2 | 5.64 Million EUR | 3.07% |
| 2017 Q1 | 5.48 Million EUR | -0.08% |
| 2016 Q1 | 2.14 Million EUR | -18.0% |
| 2016 FY | 5.48 Million EUR | 109.22% |
| 2016 Q4 | 5.48 Million EUR | 181.89% |
| 2016 Q3 | 1.94 Million EUR | -13.63% |
| 2016 Q2 | 2.25 Million EUR | 4.79% |
| 2015 FY | 2.62 Million EUR | -16.87% |
| 2015 Q1 | 3.18 Million EUR | 0.84% |
| 2015 Q2 | 3.01 Million EUR | -5.36% |
| 2015 Q3 | 2.93 Million EUR | -2.38% |
| 2015 Q4 | 2.62 Million EUR | -10.77% |
| 2014 Q1 | 6.88 Million EUR | -6.48% |
| 2014 Q3 | 2.96 Million EUR | -50.65% |
| 2014 Q2 | 6 Million EUR | -12.77% |
| 2014 FY | 3.15 Million EUR | -57.16% |
| 2014 Q4 | 3.15 Million EUR | 6.43% |
| 2013 Q3 | 8.87 Million EUR | -23.12% |
| 2013 Q2 | 11.54 Million EUR | -20.75% |
| 2013 Q1 | 14.56 Million EUR | -18.18% |
| 2013 FY | 7.36 Million EUR | -58.64% |
| 2013 Q4 | 7.36 Million EUR | -17.05% |
| 2012 Q3 | 21.72 Million EUR | -4.28% |
| 2012 FY | 17.8 Million EUR | -29.75% |
| 2012 Q1 | 23.45 Million EUR | -7.41% |
| 2012 Q2 | 22.69 Million EUR | -3.26% |
| 2012 Q4 | 17.8 Million EUR | -18.06% |
| 2011 Q3 | 27.75 Million EUR | -4.62% |
| 2011 Q1 | 15.48 Million EUR | 124.84% |
| 2011 FY | 25.33 Million EUR | 267.95% |
| 2011 Q4 | 25.33 Million EUR | -8.73% |
| 2011 Q2 | 29.1 Million EUR | 87.99% |
| 2010 Q1 | 7.6 Million EUR | -15.21% |
| 2010 FY | 6.88 Million EUR | -23.21% |
| 2010 Q4 | 6.88 Million EUR | 6.53% |
| 2010 Q3 | 6.46 Million EUR | -2.13% |
| 2010 Q2 | 6.6 Million EUR | -13.14% |
| 2009 FY | 8.96 Million EUR | -5.98% |
| 2009 Q4 | 8.96 Million EUR | 0.0% |
| 2008 FY | 9.53 Million EUR | -18.32% |
| 2007 FY | 11.67 Million EUR | -2.59% |
| 2006 FY | 11.98 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioNTech SE | 2.76 Billion EUR | 99.239% |
| CureVac N.V. | 271.53 Million EUR | 92.261% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 97.777% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 97.777% |
| BRAIN Biotech AG | 47.92 Million EUR | 56.152% |
| Formycon AG | 387.61 Million EUR | 94.579% |
| Medigene AG | 10.65 Million EUR | -97.307% |